Established by the Council in 1970, the ICCR is an international committee that contributes to the development of new contraceptives and reproductive medicine.
Today, women of reproductive age can choose between many contraceptive options. But no single method meets the needs of every woman, and contraceptive options for men remain extremely limited. Continued development of new contraceptive options is essential to ensuring access to an expanded method mix.
The Population Council's International Committee for Contraception Research (ICCR) is a global network of clinical scientists who bring novel concepts to clinical development, strengthen leadership within the sexual and reproductive health community, and assist in achieving the Millennium Development Goals (MDG). Together with Population Council scientists, the ICCR designs new contraceptive technologies and conducts clinical trials to test their safety, efficacy, and acceptability. In addition to conducting contraceptive research, the committee has strengthened the research capacity of clinical centers in developed and developing countries by building a scientific infrastructure of well-trained professionals.
Members of the ICCR and their colleagues at cooperating universities and clinics work closely with the Population Council's Center for Biomedical Research to design delivery systems, prototypes, and clinical protocols for products under development. Clinics are selected for their commitment to reproductive health care, their experience in conducting clinical trials involving contraceptives, and the high quality of their research with a rigorous adherence to ethics at every step of the testing process.
- Régine Sitruk-Ware, ICCR chairperson, Population Council, USA
- Philippe Bouchard, University of Paris, France
- Vivian Brache, PROFAMILIA, Dominican Republic
- William Bremner, University of Washington, USA
- Linan Cheng, Shanghai Institute of Planned Parenthood Research, China
- Ian Stewart Fraser, University of Sydney, Australia
- Kristina Gemzell-Danielsson, Karolinska Institute, Sweden
- Anna Glasier, University of Edinburgh, United Kingdom
- Jeffrey T. Jensen, Oregon Health & Science University, USA
- Daniel R. Mishell, Jr., University of Southern California, USA
- Malabika Roy, Indian Council of Medical Research, India
- Christina Wang, UCLA School of Medicine, USA
Through its work with the ICCR, the Population Council has developed long-acting, reversible contraceptives that have been used by more than 120 million around the world, including IUDs like ParaGard® and Mirena®; Norplant® and Jadelle® implants; and Progering®, the contraceptive vaginal ring for breastfeeding women.
In collaboration with the ICCR, the Council has developed an investigational one-year contraceptive vaginal ring. If approved by regulatory authorities, the ring would be a unique contraceptive that is effective for 13 cycles, is under a woman’s control, and does not require insertion or removal by a trained healthcare professional.
The ICCR is also investigating the utility of several products, including a transdermal Nestorone®/estradiol contraceptive gel and a long-acting ulipristal acetate contraceptive vaginal ring.